Prospects for malaria elimination in non-Amazonian regions of Latin America

Acta Tropica

Volumn 121, Issue 3, 2012, Pages 315-323

  Herrera, Sócrates ^a,b   Quiñones, Martha Lucia ^c   Quintero, Juan Pablo ^a   Corredor, Vladimir ^c   Fuller, Douglas O ^d   Mateus, Julio Cesar ^e   Calzada, Jose E ^f   Gutierrez, Juan B ^g   Llanos, Alejandro ^h   Soto, Edison ⁱ   Menendez, Clara ^j   Wu, Yimin ^k   Alonso, Pedro ^j   Carrasquilla, Gabriel ^l   Galinski, Mary ^m   Beier, John C ^d   Arévalo Herrera, Myriam ^a,b  

^a Centro de Investigación Científica Caucaseco   (Colombia)

^b School of Health   (Colombia)

^c University of Columbia   (Colombia)

^d UNIVERSITY OF MIAMI   (United States)

^e Fundación para la Educación Superior   (Colombia)

^f Gorgas Memorial Institute of Health   (Panama)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

ⁱ Tuberculosis and Malaria   (Colombia)

^j UNIVERSITY OF BARCELONA   (Spain)

^k Laboratory of Malaria Immunology and Vaccinology   (United States)

^l Santa Fe de Bogotá Foundation   (Colombia)

^m EMORY UNIVERSITY   (United States)

more..

Author keywords

Anopheles mosquitoes; Epidemiology; Latin America; Malaria; Malaria elimination; Malaria pathogenesis; Non Amazon regions; Plasmodium falciparum; Plasmodium vivax; Vector control

Indexed keywords

ARTEMISININ; MALARIA VACCINE;

DISEASE CONTROL; DISEASE TRANSMISSION; DRUG RESISTANCE; EPIDEMIOLOGY; INSECTICIDE; MALARIA; PATHOGEN;

AGRICULTURE; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CLIMATE CHANGE; DEFORESTATION; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG INDICATION; DRUG TOLERANCE; ENDEMIC DISEASE; FUNDING; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; INSECTICIDE RESISTANCE; MALARIA; MALARIA CONTROL; MEDICAL RESEARCH; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM VIVAX; POLITICAL SYSTEM; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; RAPID DIAGNOSTIC TEST; SOUTH AND CENTRAL AMERICA; VECTOR CONTROL;

ANIMALS; DELIVERY OF HEALTH CARE; DISEASE ERADICATION; DRUG RESISTANCE; EPIDEMIOLOGIC RESEARCH DESIGN; GENETIC VARIATION; HUMANS; IMIDAZOLES; INSECT VECTORS; INTERNATIONAL COOPERATION; LATIN AMERICA; MALARIA; MALARIA VACCINES; NATIONAL HEALTH PROGRAMS; NIACIN; PLASMODIUM; SOCIOECONOMIC FACTORS;

COLOMBIA; GUATEMALA [CENTRAL AMERICA]; LATIN AMERICA; PANAMA [CENTRAL AMERICA]; PERU;

ANOPHELES (GENUS); PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 84857651907     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2011.06.018     Document Type: Article

References (72)

1. Alonso P.L., Brown G., Arévalo-Herrera M., Binka F., Chitnis C., Collins F., Doumbo O., Hall L., Levine M., Mendis K., Newman R.D., Plowe C., Rodriguez M.H., Sinden R., Slutsker L., Tanner M. A research agenda to underpin malaria erradication. PLoS Med. 2011, 8:e1000406.
2. Alvarado B., Alzate A., Mateus J., Carvajal R. Efectos de una intervención educativa y de participación comunitaria en el control de la malaria en Buenaventura, Colombia. Biomédica 2006, 26:366-378.
3. Anderson, T.J., Haubold, B., Williams, J.T., Estrada-Franco, J.G., Richardson, L., Mollinedo, R., Bockarie, M., Mokili, J., Mharakurwa, S., French, N., Whitworth, J., Velez, I.D., Brockman, A.H., Nosten, F., Ferreira, M.U., Day, K.P., 2000. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol. Biol. Evol. 17, 1467-1482. http://www.ncbi.nlm.nih.gov/pubmed/11018154.
4. Arévalo-Herrera M., Chitnis C., Herrera S. Current status of Plasmodium vivax vaccine. Hum. Vaccin. 2010, 6:124-132.
5. Arévalo-Herrera M., Herrera S. Plasmodium vivax malaria vaccine development. Mol. Immunol. 2001, 38:443-455.
6. Artavanis-Tsakonas K., Tongren J.E., Riley E.M. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin. Exp. Immunol. 2003, 133:145-152.
7. Bauer S. Mining data, gathering variables and recombining information: the flexible architecture of epidemiological studies. Stud. Hist. Philos. Biol. Biomed. Sci. 2008, 39:415-428.
8. Bosman A., Mendis K.N. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am. J. Trop. Med. Hyg. 2007, 77:193-197.
9. Carrasquilla, G., 2006. Descentralización, reforma sectorial y control de la malaria en Colombia. In: Yadón, Z., Gürtler, R., Tobar, F., Medici, A. (Eds.), Descentralización y gestión del control de las enfermedades transmisibles en América Latina. PAHO, Buenos Aires, p. 320.
10. Carvajal R., Mosquera J., Carrasquilla G. The world of malaria: a health educational experience in the Colombian Pacific coast. Colomb. Med. 2010, 41:240-247.
11. Cohen J., Benns S., Vekemans J., Leach A. The malaria vaccine candidate RTS,S/AS is in phase III clinical trials. Ann. Pharm. Fr. 2010, 68:370-379.
12. Cohen J., Nussenzweig V., Nussenzweig R., Vekemans J., Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 2010, 6:90-96.
13. Coleman R.E., Maneechai N., Ponlawat A., Kumpitak C., Rachapaew N., Miller R.S., Sattabongkot J. Short report: failure of the OptiMAL rapid malaria test as a tool for the detection of asymptomatic malaria in an area of Thailand endemic for Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 2002, 67:563-565.
14. Coleman R.E., Maneechai N., Rachapaew N., Kumpitak C., Soyseng V., Miller R.S., Thimasarn K., Sattabongkot J. Field evaluation of the ICT Malaria Pf/Pv immunochromatographic test for the detection of asymptomatic malaria in a Plasmodium falciparum/vivax endemic area in Thailand. Am. J. Trop. Med. Hyg. 2002, 66:379-383.
15. Corredor V., Murillo C., Echeverry D.F., Benavides J., Pearce R.J., Roper C., Guerra A.P., Osorio L. Origin and dissemination across the Colombian Andes mountain range of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 2010, 54:3121-3125.
16. Crompton P.D., Pierce S.K., Miller L.H. Advances and challenges in malaria vaccine development. J. Clin. Invest. 2010, 120:4168-4178.
17. Dondorp A.M., Yeung S., White L., Nguon C., Day N.P., Socheat D., von Seidlein L. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 2010, 8:272-280.
18. Feachem R.G., Phillips A.A., Targett G.A., Snow R.W. Call to action: priorities for malaria elimination. Lancet 2010, 376:1517-1521.
19. Feachem R.G.A., Phillips A.A., Targett G.A. Shrinking the Malaria Map: A Prospectus on Malaria Elimination 2009, The Global Health Group, San Francisco.
20. Foley D.H., Rueda L.M., Peterson A.T., Wilkerson R.C. Potential distribution of two species in the medically important Anopheles minimus complex (Diptera: Culicidae). J. Med. Entomol. 2008, 45:852-860.
21. Gabaldon A. Malaria eradication in Venezuela: doctrine, practice, and achievements after twenty years. Am. J. Trop. Med. Hyg. 1983, 32:203-211.
22. Gabaldon A., Berti L.A., Guerrero L., Garcia Martin G. Eradication of malaria in Venezuela. Program, progress and present status. Rev. Sanid. Asist. Soc. 1961, Suppl. 3:290-336.
23. Gething P.W., Smith D.L., Patil A.P., Tatem A.J., Snow R.W., Hay S.I. Climate change and the global malaria recession. Nature 2010, 465:342-345.
24. Giron S.L., Mateus J.C., Castellar C.E. Cost-effectiveness analysis of two strategies for malaria control in the urban area of Buenaventura, Colombia. Biomedica 2006, 26:379-386.
25. Gonzalez L., Ochoa J., Franco L., Arroyave M., Restrepo E., Blair S., Maestre A. Nosocomial Plasmodium falciparum infections confirmed by molecular typing in Medellin, Colombia. Malar. J. 2005, 4:9.
26. Good M.F., Doolan D.L. Malaria vaccine design: immunological considerations. Immunity 2010, 33:555-566.
27. Guerra C.A., Howes R.E., Patil A.P., Gething P.W., Van Boeckel T.P., Temperley W.H., Kabaria C.W., Tatem A.J., Manh B.H., Elyazar I.R., Baird J.K., Snow R.W., Hay S.I. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 2010, 4:e774.
28. Herrera S., Corradin G., Arévalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol. 2007, 23:122-128.
29. Herrera S., Fernández O., Vera O., Cárdenas W., Ramírez O., Palacios R., Chen-Mok M., Corradin G., Arévalo-Herrera M. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with Montanide ISA 720 or Montanide ISA 51. Am. J. Trop. Med. Hyg. 2011, 84:12-20.
30. Kashyap V., Morales A., Hongsermeier T. On implementing clinical decision support: achieving scalability and maintainability by combining business rules and ontologies. AMIA Annu. Symp. Proc. 2006, 414-418.
31. Keeling M.J., Woolhouse M.E., Shaw D.J., Matthews L., Chase-Topping M., Haydon D.T., Cornell S.J., Kappey J., Wilesmith J., Grenfell B.T. Dynamics of the 2001 UK foot and mouth epidemic: stochastic dispersal in a heterogeneous landscape. Science 2001, 294:813-817.
32. Kroeger A., Meyer R., Mancheno M., Gonzalez M. Health education for community-based malaria control: an intervention study in Ecuador, Colombia and Nicaragua. Trop. Med. Int. Health 1996, 1:836-846.
33. Levine, R.S., Peterson, A.T., Benedict, M.Q., 2004. Geographic and ecologic distributions of the Anopheles gambiae complex predicted using a genetic algorithm. Am. J. Trop. Med. Hyg. 70, 105-109. http://www.ncbi.nlm.nih.gov/pubmed/14993618.
34. Machado R.L., Povoa M.M., Calvosa V.S., Ferreira M.U., Rossit A.R., dos Santos E.J., Conway D.J. Genetic structure of Plasmodium falciparum populations in the Brazilian Amazon region. J. Infect. Dis. 2004, 190:1547-1555.
35. Marsh K. Research priorities for malaria elimination. Lancet 2010, 376:1626-1627.
36. Mendez F., Carrasquilla G., Munoz A. Risk factors associated with malaria infection in an urban setting. Trans. R. Soc. Trop. Med. Hyg. 2000, 94:367-371.
37. Moonen B., Cohen J.M., Snow R.W., Slutsker L., Drakeley C., Smith D.L., Abeyasinghe R.R., Rodriguez M.H., Maharaj R., Tanner M., Targett G. Operational strategies to achieve and maintain malaria elimination. Lancet 2010, 376:1592-1603.
38. Moorthy V.S., Reed Z., Smith P.G. MALVAC 2008: measures of efficacy of malaria vaccines in phase 2b and phase 3 trials - scientific, regulatory and public health perspectives. Vaccine 2009, 27:624-628.
39. Nieto T., Mendez F., Carrasquilla G. Knowledge, beliefs and practices relevant for malaria control in an endemic urban area of the Colombian Pacific. Soc. Sci. Med. 1999, 49:601-609.
40. PAHO, 2006. Descentralización y gestión del control de las enfermedades transmisibles en América Latina, Buenos Aires.
41. PAHO, WHO, 2008. Integrated vector management: a comprehensive response to vector-borne diseases. In: 48th Directing Council 60th Session of the Regional Committee. WHO, Washington, DC.
42. PAMAFRO, 2009. Reporte de Resultados Fase II, No. 8.
43. Parry M.L. Climate Change 2007: Impacts, Adaptation and Vulnerability 2007, Intergovernmental Panel on Climate Change. Working Group II, Published for the Intergovernmental Panel on Climate Change [by] Cambridge University Press, Cambridge.
44. Pineros-Jimenez J.G., Arboleda M., Jaramillo J.C., Blair S. Report of five cases of severe neonatal Plasmodium vivax malaria in Uraba, Colombia. Biomedica 2008, 28:471-479.
45. Plowe C.V., Alonso P., Hoffman S.L. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J. Infect. Dis. 2009, 200:1646-1649.
46. Riley S. Large-scale spatial-transmission models of infectious disease. Science 2007, 316:1298-1301.
47. Roberts D.R., Andre R.G. Insecticide resistance issues in vector-borne disease control. Am. J. Trop. Med. Hyg. 1994, 50:21-34.
48. Rodriguez-Morales A.J., Sanchez E., Vargas M., Piccolo C., Colina R., Arria M., Franco-Paredes C. Pregnancy outcomes associated with Plasmodium vivax malaria in northeastern Venezuela. Am. J. Trop. Med. Hyg. 2006, 74:755-757.
49. Rodríguez A., Penilla R., Rodríguez H., Rodríguez M., Hemingway J., Betanzos A., Hernández-Avila J. Knowledge and beliefs about malaria transmission and practices for vector control in Southern Mexico. Salud Pública de México 2003, 45:7.
50. Roll Back Malaria, 2008. Roll Back Malaria Partnership: A Global Malaria Action Programme. WHO, Geneva.
51. Rubio-Palis Y., Zimmerman R.H. Ecoregional classification of malaria vectors in the neotropics. J. Med. Entomol. 1997, 34:499-510.
52. Ruebush T.K., Godoy H.A. Community participation in malaria surveillance and treatment. I. The Volunteer Collaborator Network of Guatemala. Am. J. Trop. Med. Hyg. 1992, 46:248-260.
53. Sacarlal J., Aide P., Aponte J.J., Renom M., Leach A., Mandomando I., Lievens M., Bassat Q., Lafuente S., Macete E., Vekemans J., Guinovart C., Sigauque B., Sillman M., Milman J., Dubois M.C., Demoitie M.A., Thonnard J., Menendez C., Ballou W.R., Cohen J., Alonso P.L. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 2009, 200:329-336.
54. Schofield L., Mueller I. Clinical immunity to malaria. Curr. Mol. Med. 2006, 6:205-221.
55. Shretta, R., Adegoke, C., Segbor, P., 2007. Global funds grands for malaria: lessons learned in the implementation of ACT polices in Ghana.
56. Sinka M.E., Rubio-Palis Y., Manguin S., Patil A.P., Temperley W.H., Gething P.W., Van Boeckel T., Kabaria C.W., Harbach R.E., Hay S.I. The dominant Anopheles vectors of human malaria in the Americas: occurrence data, distribution maps and bionomic precis. Parasit. Vectors 2010, 3:72.
57. SM2015, 2010. Salud Mesoamerica 2015.
58. Stratton L., O'Neill M.S., Kruk M.E., Bell M.L. The persistent problem of malaria: addressing the fundamental causes of a global killer. Soc. Sci. Med. 2008, 67:854-862.
59. TDR/WHO, 2009. The Malaria Eradication Research Agenda Initiative.
60. Vittor A.Y., Pan W., Gilman R.H., Tielsch J., Glass G., Shields T., Sanchez-Lozano W., Pinedo V.V., Salas-Cobos E., Flores S., Patz J.A. Linking deforestation to malaria in the Amazon: characterization of the breeding habitat of the principal malaria vector, Anopheles darlingi. Am. J. Trop. Med. Hyg. 2009, 81:5-12.
61. Wells T.N., Poll E.M. When is enough enough? The need for a robust pipeline of high-quality antimalarials. Discov. Med. 2010, 9:389-398.
62. WHO, 1998. The use of artemisinin and its derivatives as anti-malarial drugs.
63. WHO, 2005. World Malaria Report 2005. World Health Organization, Roll Back Malaria, UNICEF, Geneva, p. 294.
64. WHO, 2006. Malaria vector control and personal protection. World Health Organ Tech Rep Ser 936, 1-62, back cover.
65. WHO, 2008. World Malaria Report 2008. World Health Organization, Geneva, p. 215.
66. WHO, 2009. World Malaria Report 2009. World Health Organization, Geneva, p. 40.
67. WHO, 2011a. Global plan for artemisinin resistance containment (GPARC).
68. WHO, 2011b. Handbook on Integrated Vector Managment (IVM). World Health Organization, in press.
69. Wongsrichanalai C., Barcus M.J., Muth S., Sutamihardja A., Wernsdorfer W.H. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). Am. J. Trop. Med. Hyg. 2007, 77:119-127.
70. World Bank, S., 1993. World Development Report 1993 Investing in Health. Oxford University Press, Incorporated %@ 9780195208900, New York.
71. Wright A., Sittig D.F. SANDS: a service-oriented architecture for clinical decision support in a National Health Information Network. J. Biomed. Inform. 2008, 41:962-981.
72. Zeilhofer P., dos Santos E.S., Ribeiro A.L., Miyazaki R.D., dos Santos M.A. Habitat suitability mapping of Anopheles darlingi in the surroundings of the Manso hydropower plant reservoir, Mato Grosso, Central Brazil. Int. J. Health Geogr. 2007, 6:7.